Namit Chaudhary

Namit Chaudhary

Auto-generated profile, based on publicly available information

Namit Chaudhary

Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
NCNamit Chaudhary
Namit Chaudhary
DWDrew Weissman
Drew Weissman
KWKathryn Whitehead
Kathryn Whitehead

27 January 2023 in Science Advances
Verified
Journal Article
Closed access
JMJilian R. Melamed
Jilian R. Melamed
SYSaigopalakrishna S. Yerneni
Saigopalakrishna S. Yerneni
MAMariah L. Arral
Mariah L. Arral
SLSamuel T. LoPresti
Samuel T. LoPresti
NCNamit Chaudhary
Namit Chaudhary
KWKathryn Whitehead
Kathryn Whitehead
Systemic messenger RNA (mRNA) delivery to organs outside the liver, spleen, and lungs remains challenging. To overcome this issue, we hypothesized that altering nanoparticle chemistry and administration routes may enable mRNA-induced protein expression outside of the reticuloendothelial system. Here, we describe a strategy for delivering mRNA potently and specifically to the pancreas using lipid nanoparticles. Our results show that delivering lipid nanoparticles containing cationic helper lipids by intraperitoneal administration produces robust and specific protein expression in the pancreas. Most resultant protein expression occurred within insulin-producing β cells. Last, we found that pancreatic mRNA delivery was dependent on horizontal gene transfer by peritoneal macrophage exosome secretion, an underappreciated mechanism that influences the delivery of mRNA lipid nanoparticles. We anticipate that this strategy will enable gene therapies for intractable pancreatic diseases such as diabetes and cancer.

3 October 2024 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
NCNamit Chaudhary
Namit Chaudhary
LKLisa N. Kasiewicz
Lisa N. Kasiewicz
ANAlexandra N. Newby
Alexandra N. Newby
MAMariah L. Arral
Mariah L. Arral
SYSaigopalakrishna S. Yerneni
Saigopalakrishna S. Yerneni
KWKathryn Whitehead
Kathryn Whitehead

12 October 2023 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
DPDaria M. Strelkova Petersen
Daria M. Strelkova Petersen
NCNamit Chaudhary
Namit Chaudhary
MAMariah L. Arral
Mariah L. Arral
RWRyan M. Weiss
Ryan M. Weiss
KWKathryn Whitehead
Kathryn Whitehead
MRNA is a versatile drug molecule with therapeutic applications ranging from protein replacement therapies to in vivo gene engineering. mRNA delivery is often accomplished using lipid nanoparticles, which are formulated via mixing of aqueous and organic solutions. Although this has historically been accomplished by manual mixing for bench scale science, microfluidic mixing is required for scalable continuous manufacturing and batch to batch control. Currently, there is limited understanding on how the mixing process affects mRNA delivery efficacy, particularly in regard to tropism. To address this knowledge gap, we examined the influence of the type of mixing and microfluidic mixing parameters on the performance of lipid nanoparticles in mice. This was accomplished with a Design of Experiment approach using four nanoparticle formulations with varied ionizable lipid chemistry. We found that each formulation required unique optimization of mixing parameters, with the total delivery efficacy of each lipid nanoparticle generated with microfluidics ranging from 100-fold less to 4-fold more than manually mixed LNPs. Further, mixing parameters influenced organ tropism, with the most efficacious formulations disproportionately increasing liver delivery compared to other organs. These data suggest that mixing parameters for lipid nanoparticle production may require optimization for each unique chemical formulation, complicating translational efforts. Further, microfluidic parameters must be chosen carefully to balance overall mRNA delivery efficacy with application-specific tropism requirements.

11 April 2025 in Science Advances
Verified
Journal Article
Open access
EMEmily L. Meany
Emily L. Meany
JKJohn H. Klich
John H. Klich
CJCarolyn K. Jons
Carolyn K. Jons
TMTianyang Mao
Tianyang Mao
NCNamit Chaudhary
Namit Chaudhary
EAEric Appel
Eric Appel
Messenger RNA (mRNA) delivered in lipid nanoparticles (LNPs) rose to the forefront of vaccine candidates during the COVID-19 pandemic due to scalability, adaptability, and potency. Yet, there remain critical areas for improvements of these vaccines in durability and breadth of humoral responses. In this work, we explore a modular strategy to target mRNA/LNPs to antigen-presenting cells with an injectable polymer-nanoparticle (PNP) hydrogel technology, which recruits key immune cells and forms an immunological niche in vivo. We characterize this niche on a single-cell level and find it is highly tunable through incorporation of adjuvants like MPLAs and 3M-052. Delivering commercially available severe acute respiratory syndrome coronavirus 2 mRNA vaccines in PNP hydrogels improves the durability and quality of germinal center reactions, and the magnitude, breadth, and durability of humoral responses. The tunable immune niche formed within PNP hydrogels effectively skews immune responses based on encapsulated adjuvants, creating opportunities to precisely modulate mRNA/LNP vaccines for various indications from infectious diseases to cancers.

9 August 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
NLNicholas G. Lamson
Nicholas G. Lamson
KFKatherine C. Fein
Katherine C. Fein
JGJohn Gleeson
John Gleeson
ANAlexandra N. Newby
Alexandra N. Newby
SXSijie Xian
Sijie Xian
KWKathryn Whitehead
Kathryn Whitehead
Although patients generally prefer oral drug delivery to injections, low permeability of the gastrointestinal tract makes this method impossible for most biomacromolecules. One potential solution is codelivery of macromolecules, including therapeutic proteins or nucleic acids, with intestinal permeation enhancers; however, enhancer use has been limited clinically by modest efficacy and toxicity concerns surrounding long-term administration. Here, we hypothesized that plant-based foods, which are well tolerated by the gastrointestinal tract, may contain compounds that enable oral macromolecular absorption without causing adverse effects. Upon testing more than 100 fruits, vegetables, and herbs, we identified strawberry and its red pigment, pelargonidin, as potent, well-tolerated enhancers of intestinal permeability. In mice, an oral capsule formulation comprising pelargonidin and a 1 U/kg dose of insulin reduced blood glucose levels for over 4 h, with bioactivity exceeding 100% relative to subcutaneous injection. Effects were reversible within 2 h and associated with actin and tight junction rearrangement. Furthermore, daily dosing of mice with pelargonidin for 1 mo resulted in no detectable side effects, including weight loss, tissue damage, or inflammatory responses. These data suggest that pelargonidin is an exceptionally effective enhancer of oral protein uptake that may be safe for routine pharmaceutical use.